Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Praluent can stay on market for now, says US court

Praluent can stay on market for now, says US court

Praluent was approved in the US first, but Amgen has so far won the key rounds in the legal dispute over PCSK9 inhibitor intellectual property rights. ... This decision is important for patients in the US who will continue to have access to Praluent

Latest news

  • New outcomes data could unlock Repatha's potential, says Amgen New outcomes data could unlock Repatha's potential, says Amgen

    PCSK9 inhibitor Repatha (evolocumab) was approved on the strength of data showing it could reduce low-density lipoprotein cholesterol (LDL-c), but health insurers and pharmacy benefit managers in the US ... for their rival PCSK9 inhibitor Praluent

  • Amgen wins block on sales of Sanofi/Regeneron's Praluent Amgen wins block on sales of Sanofi/Regeneron's Praluent

    Amgen has won another round in its lawsuit with Sanofi and Regeneron over patent rights to the new PCSK9 inhibitor class of cholesterol-lowering drugs. ... The decision follows an earlier victory for Amgen as it defended patents on its rival PCSK9

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    Amgen's Repatha unclogs blocked arteries, says study. Looks to boost sales after trial shows clear clinical advantage of PCSK9 inhibitor over statins. ... Despite blockbuster sales projections, PCSK9 inhibitor Repatha (evolocumab) and rival drug Praluent

  • Pfizer dropping bococizumab casts shadow over PCSK9 class Pfizer dropping bococizumab casts shadow over PCSK9 class

    Pfizer dropping bococizumab casts shadow over PCSK9 class. US payer resistance and diminishing efficacy prompt decision on would-be blockbuster. ... The company's chief executive Ian Read said that experience with already-marketed drugs in the PCSK9

  • NICE backs five new drugs after discounts agreed NICE backs five new drugs after discounts agreed

    drugs - ALK inhibitor Zykadia (ceritinib) for lung cancer and melanoma treatment Mekinist (trametinib), a MEK inhibitor. ... It also gave the nod to two cholesterol-lowering PCSK9 inhibitors - Sanofi's Praluent (alirocumab) and Amgen's Repatha (evolocumab

More from news
Approximately 10 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics